Anti-inflammatory effects of nicotine in obesity and ulcerative colitis

Journal of Translational Medicine

Volumn 9, Issue 1, 2011, Pages

  Lakhan, Shaheen E ^a   Kirchgessner, Annette ^a,b  

^a Global Neuroscience Initiative Foundation   (United States)

^b SETON HALL UNIVERSITY   (United States)

Author keywords

7 nicotinic acetylcholine receptor; Enteric nervous system; Pro inflammatory cytokines; Ulcerative colitis

Indexed keywords

BUNGAROTOXIN RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; NICOTINE; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; CHOLINE; NICOTINIC RECEPTOR;

ANTIINFLAMMATORY ACTIVITY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; HUMAN; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; NONHUMAN; OBESITY; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; ULCERATIVE COLITIS; WEIGHT REDUCTION; ANIMAL; METABOLISM; PATHOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CHOLINE; COLITIS, ULCERATIVE; HUMANS; NICOTINE; OBESITY; RECEPTORS, NICOTINIC;

EID: 79960891073     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-9-129     Document Type: Review

References (96)

1. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, Capeau J, Feve B. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw 2006, 17:4-12.
2. Federico A, D'Aiuto E, Borriello F, Barra G, Gravina AG, Romano M, De Palma R. Fat: a matter of disturbance of the immune system. World J Gastroenterl 2010, 16:4762-4772.
3. Gil A, Maria Aquilera C, Gil-Campos M, Canete R. Altered signaling and gene expression associated with the immune system and the inflammatory response in obesity. Br J Nutr 2007, 98(Suppl 1):S121-126.
4. Wang S, Liu Z, Wang L, Zhang X. NF-kappaB signaling pathway, inflammation and colorectal cancer. Cell Mol Immunol 2009, 6:327-334. 10.1038/cmi.2009.43, 19887045.
5. Brown SJ, Mayer L. The immune response in inflammatory bowel disease. Am J Gastroenterol 2007, 102:2058-2069. 10.1111/j.1572-0241.2007.01343.x, 17561966.
6. Papadakis KA, Targan SR. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 2000, 51:289-298. 10.1146/annurev.med.51.1.289, 10774465.
7. Wang XFYZ, Xue B, Shi H. Activation of the cholinergic antiinflammatory pathway ameliorates obesity-induced inflammation and insulin resistance. Endocrinology 2011, 152:836-846. 10.1210/en.2010-0855, 21239433.
8. McGrath J, McDonald JW, Macdonald JK. Transdermal nictoine for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2004, 18:CD004722.
9. Pullan RD, Rhodes J, Ganesh S, Mani V, Morris JS, Williams GT, Newcombe RG, Russell MA, Feyerabend C, Thomas GA. Transdermal nicotine for active ulcerative colitis. N Engl J Med 1994, 24:811-815.
10. Ingram JR, Rhodes J, Evans BK, Thomas GAO. Nicotine enemas for treatment of ulcerative colitis: a study of the pharmacokinetics and adverse events associated with three doses of nicotine. Aliment Pharmacol Ther 2008, 20:859-865.
11. Thomas GAO, Rhodes J, Ingram JR. Mechanism of disease: nicotine- a review of its actions in the context of gastrointestinal disease. Nat Clin Practice 2005, 2:536-544.
12. Sandborn W. Nicotine therapy for ulcerative colitis: a review of rationale, mechanisms, pharmacology, and clinical results. Am J Gastroenterol 1999, 94:1161-1171. 10.1111/j.1572-0241.1999.01059.x, 10235187.
13. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, Wang H, Abumrad N, Eaton JW, Tracey KJ. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000, 405:458-462. 10.1038/35013070, 10839541.
14. Tracey KJ, Czura CJ, Ivanova S. Mind over immunity. FASEB J 2001, 15:1575-1576. 10.1096/fj.01-0148hyp, 11427490.
15. de Jonge WJ, van der Zanden EP, The FO, Bijlsma MF, van Westerloo DJ, Bennink RJ, Berthoud HR, Uematsu S, Akira S, van den Wijngaard RM, et al. Stimulation of the vagus nerve attenuates macrophage activation by activating the Jak2-STAT3 signaling pathway. Nat Immunol 2005, 6:844-851. 10.1038/ni1229, 16025117.
16. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, Li JH, Wang H, Yang H, Ulloa L, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003, 421:384-388. 10.1038/nature01339, 12508119.
17. Fujii YX, Fujigaya H, Moriwaki Y, Misawa H, Kasahara T, Grando SA, Kawashima K. Enhanced serum antigen-specific IgG1 and proinflammatory cytokine production in nicotinic acetylcholine receptor alpha7 subunit gene knockout mice. J Neuroimmunol 2007, 189:69-74. 10.1016/j.jneuroim.2007.07.003, 17675251.
18. Alberg A. The influence of cigarette smoking on circulating concentrations of antioxidant micronutrients. Toxicology 2002, 15:121-137.
19. Vassallo R, Kroening PR, Parambil J, Kita H. Nicotine and oxidative cigarette smoke constituents induce immune-modulatory and pro-inflammatory dendritic cell responses. Mol Immunol 2008, 45:3321-3329. 10.1016/j.molimm.2008.04.014, 2857673, 18533267.
20. Mozaffarieh M, Konieczka K, Hauenstein D, Schoetzau A, Flammer J. Half a pack of cigarettes a day more than doubles DNA breaks in circulating leukocytes. Tob Induc Dis 2010, 8:14. 10.1186/1617-9625-8-14, 2996352, 21083877.
21. Metz CN, Tracey KJ. It takes nerve to dampen inflammation. Nat Immunol 2005, 6:756-757.
22. Pavlov VA, Wang H, Czura CJ, Friedman SG, Tracey KJ. The cholinergic anti-inflammatory pathway: a missing link in neuroimmunomodulation. Mol Med 2003, 9:125-134. 1430829, 14571320.
23. Carlson NG, Bacchi A, Rogers SW, Gahring LC. Nicotine blocks TNF-alpha mediated neuroprotection to NMDA by an alpha-bungarotoxin-sensitive pathway. J Neurobiol 1998, 35:29-36. 10.1002/(SICI)1097-4695(199804)35:1<29::AID-NEU3>3.0.CO;2-D, 9552164.
24. Huston JM, Ochani M, Rosas-Ballina M, Liao H, Ochani K, Pavlov VA, Gallowitsch-Puerta M, Ashok M, Czura CJ, Foxwell B, et al. Splenectomy inactivates the cholinergic antiinflammatory pathway during lethal endotoxemia and polymicrobial sepsis. J Exp Med 2006, 203:1623-1628. 10.1084/jem.20052362, 2118357, 16785311.
25. de Jonge WJ, Ulloa L. The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation. Br J Pharmacol 2007, 15:915-929.
26. Tracey KJ. Physiology and immunology of the cholinergic anti-inflammatory pathway. J Clin Invest 2007, 117:289-296. 10.1172/JCI30555, 1783813, 17273548.
27. Johnston GR, Webster NR. Cytokines and the immunomodulatory function of the vagus nerve. Br J Anaesthesia 2009, 102:453-462.
28. Czura CJ, Tracey KJ. Autonomic neural regulation of immunity. J Intern Med 2005, 257:156-166. 10.1111/j.1365-2796.2004.01442.x, 15656874.
29. Joe Y, Kim HJ, Kim S, Chung J, Ko MS, Lee WH, Chang KC, Park JW, Chung HT. Tristetraprolin mediates the anti-inflammatory effects of nicotine in LPS-stimulated macrophages. J Biol Chem 2011,
30. Taylor GA, Carballo E, Lee DM, Lai WS, Thompson MJ, Patel DD, Schenkman DI, Gilkeson GS, Broxmeyer HE, Haynes BF, et al. A pathogenic role for TNF alpha in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. Immunity 1996, 4:445-454. 10.1016/S1074-7613(00)80411-2, 8630730.
31. Wang H, Liao H, Ochani M, Justiniani M, Lin X, Yang L, Al-Abed Y, Wang H, Metz C, Miller EJ, et al. Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat Med 2004, 10:1216-1221. 10.1038/nm1124, 15502843.
32. Kirchgessner AL, Liu M-T. Immunohistochemical localization of nicotinic acetylcholine receptors in the guinea pig bowel and pancreas. J Comp Neurol 1998, 390:497-514. 10.1002/(SICI)1096-9861(19980126)390:4<497::AID-CNE4>3.0.CO;2-W, 9450532.
33. Lindstrom J. Neuronal nicotinic acetylcholine receptors. Ion Channels 1996, 4:377-450.
34. Sadis C, Teske G, Kubjak C, Claessen N, Moore F, Loi P, Diallo B, Barvais L, Goldman M, Florquin S, et al. Nicotine protects kidney from renal ischemia/reperfusion injury through the cholinergic anti-inflammatory pathway. PLOS One 2007, 2.
35. Luyer MDGJ, Hadfoune M, Jacobs JA, Dejong CH, Buurman WA. Nutritional stimulation of cholecystokinin receptors inhibits inflammatin via the vagus nerve. J Exp Med 2005, 202:1023-1029. 10.1084/jem.20042397, 2213207, 16216887.
36. van Westerloo DJ, Giebelen IA, Florquin S, Daalhuisen J, Bruno MJ, de Vos AF, Tracey KJ, van der Poll T. The cholinergic anti-inflammatory pathway regulates the host response during septic peritonitis. J Infect Dis 2005, 191:2138-2148. 10.1086/430323, 15898001.
37. Ghia JE, Blennerhassett P, Kumar-Ondiveeran H, Verdu EF, Collins SM. The vagus nerve: a tonic inhibitory influence associated with inflammatory bowel disease in a murine model. Gastroenterology 2006, 131:1122-1130. 10.1053/j.gastro.2006.08.016, 17030182.
38. Ghia JE, Blennerhassett P, El-Sharkawy RT, Collins SM. The protective effect of the vagus nerve in a murine model of chronic relapsing colitis. Am J Physiol Gastrointest Liver Physiol 2007, 293:G711-G718. 10.1152/ajpgi.00240.2007, 17673544.
39. Song XM, Li JG, Wang YL, Hu ZF, Zhou Q, Du ZH, Jia BH. The protective effect of the cholinergic anti-inflammatory pathway against septic shock in rats. Shock 2008, 30(4):468-472. 10.1097/SHK.0b013e31816d5e49, 18391858.
40. Wang DW, Zhou RB, Yao YM, Zhu XM, Yin YM, Zhao GJ, Sheng ZY. Stimulation of alpha 7 nicotinic acetylcholine receptor by nicotine increases suppressive capacity of naturally occurring CD4+CD25+ regulatory T cells in mice in vitro. J Pharmacol Exp Ther 2010, 335:553-561. 10.1124/jpet.110.169961, 20843956.
41. Nizri E, Irony-Tur-Sinai M, Lory O, Orr-Urtreger A, Lavi E, Brenner T. Activation of the cholinergic anti-inflammatory system by nicotine attenuates neuroinflammation via suppression of Th1 and Th17 responses. J Immunol 2009, 183:6681-6688. 10.4049/jimmunol.0902212, 19846875.
42. Berthoud HR, Powley TL. Characterization of vagal innervation to the rat celiac, suprarenal and mesenteric ganglia. J Auton Nerv Syst 1993, 42:153-169. 10.1016/0165-1838(93)90046-W, 8450174.
43. Vida G, Pena G, Deitch EA, Ulloa L. Alpha 7-cholinergic receptor mediates vagal induction of splenic norepinephrine. J Immunol 2011, 186:4340-4346. 10.4049/jimmunol.1003722, 3083451, 21339364.
44. Saeed RWVS, Peng-Nemeroff T, Sherry B, Balakhaneh D, et al. Cholinergic stimulation blocks endothelial cell activation and leukocyte recruitment during inflammation. J Exp Med 2005, 201:1113-1123. 10.1084/jem.20040463, 2213139, 15809354.
45. Huston JM, Rosas-Ballina M, Xue X, Dowling O, Ochani K, Ochani M, Yeboah MM, Chatterjee PK, Tracey KJ, Metz CN. Cholinergic neural signals to the spleen down-regulate leukocyte trafficking via CD11b. J Immunol 2009, 183:552-559. 10.4049/jimmunol.0802684, 2806576, 19542466.
46. WHO Obesity 2008, WHO.
47. Whitmer RA, Gunderson EP, Quesenberry CP, Zhou J, Yaffe K. Body mass index in midlife and risk of Alzheimer disease and vascular dementia. Curr Alzheimer Res 2007, 4:103-109. 10.2174/156720507780362047, 17430231.
48. Delgado-Aros S, Locke GR, Camilleri M, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ. Obesity is associated with increased risk of gastrointestinal symptoms: a population-based study. Am J Gastroenterol 2004, 99:1801-1806. 10.1111/j.1572-0241.2004.30887.x, 15330922.
49. Furness JB. The enteric nervous system: normal functions and enteric neuropathies. Neurogastroenterol Motil 2008, 20(Suppl 1):32-38.
50. WHO The World Health Report 2002 2002, WHO.
51. Wager-Srdar SA, Levine AS, Morley JE, Hoidal JR, Niewoehner DE. Effects of cigarette smoke and nicotine on feeding and energy. Physiol Behav 1984, 32:389-395. 10.1016/0031-9384(84)90252-X, 6463126.
52. Chen H, Vlahos R, Bozinovski S, Jones J, Anderson GP, Morris MJ. Effect of short-term cigarette smoke exposure on body weight, appetite and brain neuropeptide Y in mice. Neuropsychopharmacology 2005, 30:713-719.
53. Hajek P, Jackson P, Belcher M. Long-term us of nicotine chewing gum: occurrence, determinants, and effect on weight gain. JAMA 1988, 260:1593-1596. 10.1001/jama.260.11.1593, 3411739.
54. Chen H, Hansen MJ, Jones JE, Vlahos R, Bozinovski S, Anderson GP, Morris MJ. Cigarette smoke exposure reprograms the hypothalamic neuropeptide Y axis to promote weight loss. Am J Respir Crit Care Med 2006, 173:1248-1254. 10.1164/rccm.200506-977OC, 16531608.
55. Filozof C, Fernandez Pinilla MC, Fernandez-Cruz A. Smoking cessation and weight gain. Obes Rev 2004, 5:95-103. 10.1111/j.1467-789X.2004.00131.x, 15086863.
56. Fulkerson JA, French SA. Cigarette smoking for weight loss or control among adolescents: gender and racial/ethnic differences. J Adolesc Health 2003, 32:306-313. 10.1016/S1054-139X(02)00566-9, 12667735.
57. Stamford BA, Matter S, Fell RD, Papanek P. Effects of smoking cessation on weight gain, metabolic rate, caloric consumption, and blood lipids. Am J Clin Nutr 1986, 43:486-494.
58. Mineur YSAA, Rao Y, Salas R, DiLeone RJ, et al. Nicotine decreases food intake through activation of POMC neurons. Science 2011, (332):1330-1332.
59. Huang HXY, van den Pol A. Nicotine excites hypothalamic arcuate anorexigenic proopiomelanocortin neurons and orexigenic neuropeptide Y neurons: similarities and differences. J Neurophysiol 2011,
60. Jang MH. Nicotine administration decreases neuropeptide Y expression and increases leptin receptor expression in the hypothalmus of food-deprived rats. Brain Res 2003, 964:311-315. 10.1016/S0006-8993(02)04122-7, 12576193.
61. Kane JK, Parker SL, Li MD. Hypothalamic orexin-A binding sites are down-regulated by chronic nicotine treatment in the rat. Neurosci Lett 2001, 298:1-4. 10.1016/S0304-3940(00)01730-4, 11154821.
62. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 2010, 72:219-246. 10.1146/annurev-physiol-021909-135846, 20148674.
63. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003, 112:1796-1808. 296995, 14679176.
64. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003, 1123:1821-1830.
65. Arkan MC, Hevener AL, Greten FR, Maeda S, Li ZW, Long JM, Wynshaw-Boris A, Poli G, Olefsky J, Karin M. IKK-b links inflammation to obesity-induced insulin resistance. Nat Med 2005, 11:191-198. 10.1038/nm1185, 15685170.
66. Solinas GVC, Neels JG, Bandyopadhyay GK, Luo JL, Naugler W, et al. JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity. Cell Metab 2007, 6:386-397. 10.1016/j.cmet.2007.09.011, 17983584.
67. Rosas-Ballina M, Tracey KJ. The neurology of the immune system: neural reflexes regulate immunity. Neuron 2009, 64:28-32. 10.1016/j.neuron.2009.09.039, 19840545.
68. Bencherif M, Lippiello PM, Lucas R, Marrero MB. Alpha 7 nicotinic receptors as novel therapeutic targets for inflammation-based diseases. Cell Mol Life Sci 2010, 10.
69. Chiolero AFD, Paccaud F, Cornuz J. Consequences of smoking for body weight, body fat distribution, and insulin resistance. Am J Clin Nutr 2008, 87:801-809.
70. Targher GAM, Zenere MB, Bonadonna RC, Muggeo M, Bonora E. Cigarette smoking and insulin resistance in patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1997, 82:3619-3624. 10.1210/jc.82.11.3619, 9360516.
71. Birtwistle J, Hall K. Does nicotine have beneficial effects in the treatment of certain diseases?. Br J Nurs 1996, 5:1195-1202.
72. Birtwistle J. The role of cigarettes and nicotine in the onset and treatment of ulcerative colitis. Postgrad Med J 1996, 72:714-718. 10.1136/pgmj.72.854.714, 2398677, 9015463.
73. Wolf JM, Lashner BA. Inflammatory bowel disease: sorting out the treatment options. Cleve Clin J Med 2002, 69:621-631. 10.3949/ccjm.69.8.621, 12184470.
74. Hilsden RJ, Hodgins DC, Timmer A, Sutherland LR. Helping patients with Crohn's disease quit smoking. Am J Gastroenterol 2000, 95:352-358.
75. Cosnes J. Tobacco and IBD: relevance in the understanding of disease mechanisms and clinical practice. Best Pract Res Clin Gastroenterol 2004, 18:481-496. 10.1016/j.bpg.2003.12.003, 15157822.
76. Mahid SS, Minor KS, Stevens PI, Galandiuk S. The role of smoking in Crohn's disease as defined by clinical variables. Dig Dis Sci 2007, 52:2897-2903. 10.1007/s10620-006-9624-0, 17401688.
77. Matsunaga KKT, Friedman H, Yamamoto Y. Involvement of nicotinic acetycholine receptors in suppression of antimicrobial activity and cytokine responses of alveolar macrophages to Legionella pneumophila infection by nicotine. J Immunol 2001, 167:6518-6524.
78. Hanauer S. Inflammatory bowel disease. N Engl J Med 1996, 334:841-848. 10.1056/NEJM199603283341307, 8596552.
79. Nejdfors PWQ, Ekelund M, et al. Increased colonic permeability in patients with ulcerative colitis: an in vitro study. Scan J Gastroenterol 1998, 33:749-753.
80. Herrinton LJLL, Lewis JD, Griffin PM, Allison J. Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996-2002. Am J Gastro 2008, 103:1998-2006.
81. Ahnfelt-Ronne I, Nielsen OH, Christensen A, Langholz E, Binder V, Riis P. Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid. Gastroenterology 1990, 98:1162-1169.
82. Green JT, Thomas GA, Rhodes J, Williams GT, Evans BK, Russell MA, Feyerabend C, Rhodes P, Sandborn WJ. Nicotine enemas for active ulcerative colitis- a pilot study. Aliment Pharmacol Ther 1997, 11:859-863. 10.1046/j.1365-2036.1997.00220.x, 9354193.
83. Ulloa L, Wang P. The neuronal strategy for inflammation. Novartis Found Symp 2007, 280:233-237.
84. Ben-Horin S, Chowers Y. Neuroimmunology of the gut: physiology, pathology, and pharmacology. Curr Opin Pharmacol 2008, 8:490-495. 10.1016/j.coph.2008.07.010, 18675937.
85. Bian XBJ, Carrasquillo M, Galligan JJ. Postnatal downregulation of inhibitory neuromuscular transmission to the longitudinal muscle of the guinea pig ileum. Neurogastroenterol Motil 2009, 21:969-977. 10.1111/j.1365-2982.2009.01296.x, 19374637.
86. Ghia JE, Blennerhassett P, Deng Y, Verdu EF, Khan WI, Collins SM. Reactivation of inflammatory bowel disease in a mouse model of depression. Gastroenterology 2009, 136:2280-2288. 10.1053/j.gastro.2009.02.069, 19272381.
87. Aldous MC, Prescott RJ, Roberts S, Samuel K, Waterfall M, Satsangi J. Does nicotine influence cytokine profile and subsequent cell cycling/apoptotic responses in inflammatory bowel disease?. Inflamm Bowel Dis 2008, 14:1469-1482. 10.1002/ibd.20523, 18618634.
88. Gareau MG, Jury J, Perdue MH. Neonatal maternal separation of rat pups results in abnormal cholinergic regulation of epithelial permeability. Am J Physiol Gastrointest Liver Physiol 2007, 293:G198-203. 10.1152/ajpgi.00392.2006, 17510196.
89. van der Zanden EP, Snoek SA, Heinsbroek SE, Stanisor OI, Verseijden C, Boeckxstaens GE, Peppelenbosch MP, Greaves DR, Gordon S, De Jonge WJ. Vagus nerve activity augments intestinal macrophage phagocytosis via nicotinic acetylcholine receptor alpha4 beta2. Gastroenterology 2009, 137:1029-1039. 10.1053/j.gastro.2009.04.057, 19427310.
90. Snoek SA, Verstege MI, van der Zanden EP, Deeks N, Bulmer DC, Skynner M, Lee K, Te Velde AA, Boeckxstaens GE, de Jonge WJ. Selective alpha 7 nicotinic acetylcholine receptor agonists worsen disease in experimental colitis. Br J Pharmacol 2010, 160:322-333. 10.1111/j.1476-5381.2010.00699.x, 2874854, 20423343.
91. Orr-Urtreger A, Kedmi M, Rosner S, Karmeli F, Rachmilewitz D. Increased severity of experimental colitis in alpha 5 nicotinic acetylcholine receptor subunit-deficient mice. Neuroreport 2005, 16:1123-1127. 10.1097/00001756-200507130-00018, 15973160.
92. Lakhan SE, Kirchgessner A. Neuroinflammation in inflammatory bowel disease. J Neuroinflammation 2010, 7:37. 10.1186/1742-2094-7-37, 2909178, 20615234.
93. Geboes K, Collins S. Structural abnormalities of the nervous system in Crohn's disease and ulcerative colitis. Neurogastroenterol Motil 1998, 10(3):189-202. 10.1046/j.1365-2982.1998.00102.x, 9659662.
94. Tornblom H, Lindberg G, Nyberg B, Veress B. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 2002, 123(6):1972-1979. 10.1053/gast.2002.37059, 12454854.
95. De Giorgio R, Camilleri M. Human enteric neuropathies: morphology and molecular pathology. Neurogastroenterol Motil 2004, 16(5):515-531. 10.1111/j.1365-2982.2004.00538.x, 15500508.
96. Xu W, Gelber S, Orr-Urtreger A, Armstrong D, Lewis RA, Ou CN, Patrick J, Role L, De Biasi M, Beaudet AL. Megacystis, mydriasis, and ion channel defect in mice lacking the alpha3 neuronal nicotinic acetylcholine receptor. Proc Natl Acad Sci 1999, 96:5746-5751. 10.1073/pnas.96.10.5746, 21931, 10318955.